JP2020531535A5 - - Google Patents

Download PDF

Info

Publication number
JP2020531535A5
JP2020531535A5 JP2020511435A JP2020511435A JP2020531535A5 JP 2020531535 A5 JP2020531535 A5 JP 2020531535A5 JP 2020511435 A JP2020511435 A JP 2020511435A JP 2020511435 A JP2020511435 A JP 2020511435A JP 2020531535 A5 JP2020531535 A5 JP 2020531535A5
Authority
JP
Japan
Prior art keywords
hematopoietic
cell population
hematopoietic cell
cells
exon
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2020511435A
Other languages
English (en)
Japanese (ja)
Other versions
JP2020531535A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2018/048317 external-priority patent/WO2019046285A1/en
Publication of JP2020531535A publication Critical patent/JP2020531535A/ja
Publication of JP2020531535A5 publication Critical patent/JP2020531535A5/ja
Priority to JP2024076658A priority Critical patent/JP2024105479A/ja
Pending legal-status Critical Current

Links

JP2020511435A 2017-08-28 2018-08-28 Cd33標的剤と共に使用するためのcd33エクソン2欠損型ドナー幹細胞 Pending JP2020531535A (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2024076658A JP2024105479A (ja) 2017-08-28 2024-05-09 Cd33標的剤と共に使用するためのcd33エクソン2欠損型ドナー幹細胞

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201762551075P 2017-08-28 2017-08-28
US62/551,075 2017-08-28
PCT/US2018/048317 WO2019046285A1 (en) 2017-08-28 2018-08-28 CD33 EXON 2 DONOR STEM CELLS FOR USE WITH CD33 TARGETING AGENTS

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2024076658A Division JP2024105479A (ja) 2017-08-28 2024-05-09 Cd33標的剤と共に使用するためのcd33エクソン2欠損型ドナー幹細胞

Publications (2)

Publication Number Publication Date
JP2020531535A JP2020531535A (ja) 2020-11-05
JP2020531535A5 true JP2020531535A5 (cg-RX-API-DMAC7.html) 2021-09-30

Family

ID=65525985

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2020511435A Pending JP2020531535A (ja) 2017-08-28 2018-08-28 Cd33標的剤と共に使用するためのcd33エクソン2欠損型ドナー幹細胞
JP2024076658A Pending JP2024105479A (ja) 2017-08-28 2024-05-09 Cd33標的剤と共に使用するためのcd33エクソン2欠損型ドナー幹細胞

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2024076658A Pending JP2024105479A (ja) 2017-08-28 2024-05-09 Cd33標的剤と共に使用するためのcd33エクソン2欠損型ドナー幹細胞

Country Status (4)

Country Link
US (2) US11718659B2 (cg-RX-API-DMAC7.html)
EP (1) EP3676372A4 (cg-RX-API-DMAC7.html)
JP (2) JP2020531535A (cg-RX-API-DMAC7.html)
WO (1) WO2019046285A1 (cg-RX-API-DMAC7.html)

Families Citing this family (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL258491B2 (en) 2015-10-16 2023-09-01 Univ Columbia Preparations and methods for inhibiting antigens of a particular lineage
KR102709603B1 (ko) 2017-02-28 2024-09-27 보르 바이오파마 인크. 계통 특이적 단백질의 억제를 위한 조성물 및 방법
EP3676372A4 (en) * 2017-08-28 2021-06-02 The Trustees of Columbia University in the City of New York CD33 EXON 2 DEFICIENT DONOR STEM CELLS FOR USE WITH AGENTS AGAINST CD33
CA3110837A1 (en) 2018-08-28 2020-03-05 Vor Biopharma Inc. Genetically engineered hematopoietic stem cells and uses thereof
US11866494B2 (en) * 2018-08-31 2024-01-09 Innovative Cellular Therapeutics Holdings, Ltd. CAR T therapy through uses of co-stimulation
JP7784707B2 (ja) * 2019-01-16 2025-12-12 ザ・トラスティーズ・オブ・コロンビア・ユニバーシティ・イン・ザ・シティ・オブ・ニューヨーク 系統特異的抗原の阻害のための組成物および方法
AU2020280103A1 (en) 2019-05-23 2021-12-23 Vor Biopharma Inc. Compositions and methods for CD33 modification
AU2020338011A1 (en) 2019-08-28 2022-03-10 Vor Biopharma Inc. Compositions and methods for CLL1 modification
WO2021041977A1 (en) 2019-08-28 2021-03-04 Vor Biopharma, Inc. Compositions and methods for cd123 modification
US12551560B2 (en) 2019-09-09 2026-02-17 Scribe Therapeutics Inc. Compositions and methods for use in immunotherapy
EP4048790A4 (en) * 2019-10-22 2024-03-27 Fred Hutchinson Cancer Center BASE EDITOR-MEDIATED CD33 REDUCTION FOR SELECTIVE PROTECTION OF THERAPEUTIC CELLS
CN116157135A (zh) * 2020-06-03 2023-05-23 纽约市哥伦比亚大学理事会 使用基于crispr的碱基编辑器系统抑制谱系特异性抗原的组合物和方法
EP4204564A1 (en) 2020-08-28 2023-07-05 Vor Biopharma Inc. Compositions and methods for cd123 modification
EP4204565A1 (en) 2020-08-28 2023-07-05 Vor Biopharma Inc. Compositions and methods for cll1 modification
WO2022056489A1 (en) 2020-09-14 2022-03-17 Vor Biopharma, Inc. Compositions and methods for cd38 modification
EP4211245A1 (en) 2020-09-14 2023-07-19 Vor Biopharma Inc. Compositions and methods for cd5 modification
WO2022061115A1 (en) 2020-09-18 2022-03-24 Vor Biopharma Inc. Compositions and methods for cd7 modification
WO2022067240A1 (en) 2020-09-28 2022-03-31 Vor Biopharma, Inc. Compositions and methods for cd6 modification
WO2022072643A1 (en) 2020-09-30 2022-04-07 Vor Biopharma Inc. Compositions and methods for cd30 gene modification
CA3199623A1 (en) * 2020-10-27 2022-05-05 Vor Biopharma Inc. Compositions and methods for treating hematopoietic malignancy
CN116600821A (zh) * 2020-10-27 2023-08-15 Vor生物制药股份有限公司 用于治疗造血系统恶性肿瘤的组合物和方法
WO2022094245A1 (en) 2020-10-30 2022-05-05 Vor Biopharma, Inc. Compositions and methods for bcma modification
AU2021413252A1 (en) 2020-12-31 2023-06-08 Vor Biopharma Inc. Compositions and methods for cd34 gene modification
CN115443333B (zh) * 2021-04-27 2025-04-25 上海驯鹿生物技术有限公司 一种基因编辑的造血干细胞及其与car-t细胞的联合应用
PE20252304A1 (es) * 2021-04-28 2025-09-22 Eisai Randd Man Co Ltd Oligonucleotidos antisentido y su uso para el tratamiento de trastornos neurodegenerativos
EP4430186A1 (en) 2021-11-09 2024-09-18 Vor Biopharma Inc. Compositions and methods for erm2 modification
WO2024015925A2 (en) 2022-07-13 2024-01-18 Vor Biopharma Inc. Compositions and methods for artificial protospacer adjacent motif (pam) generation
IL320040A (en) * 2022-10-05 2025-06-01 Musc Found For Res Dev Superantigen conjugate vaccine for cancer treatment
WO2024168312A1 (en) * 2023-02-09 2024-08-15 Vor Biopharma Inc. Methods for treating hematopoietic malignancy
WO2025030010A1 (en) 2023-08-01 2025-02-06 Vor Biopharma Inc. Compositions comprising genetically engineered hematopoietic stem cells and methods of use thereof

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP6831777B2 (ja) 2014-07-21 2021-02-17 ノバルティス アーゲー Cd33キメラ抗原受容体を使用する癌の処置
US10201606B2 (en) * 2014-11-26 2019-02-12 Miltenyi Biotec Gmbh Combination immunotherapy of antigen-recognizing receptors and hematopoietic cells for the treatment of diseases
IL258491B2 (en) * 2015-10-16 2023-09-01 Univ Columbia Preparations and methods for inhibiting antigens of a particular lineage
EP3439700A4 (en) * 2016-04-06 2020-01-01 University of Florida Research Foundation, Inc. BIOMARKER FOR ANTILEUCEMIC THERAPY
KR102709603B1 (ko) * 2017-02-28 2024-09-27 보르 바이오파마 인크. 계통 특이적 단백질의 억제를 위한 조성물 및 방법
EP3676372A4 (en) * 2017-08-28 2021-06-02 The Trustees of Columbia University in the City of New York CD33 EXON 2 DEFICIENT DONOR STEM CELLS FOR USE WITH AGENTS AGAINST CD33

Similar Documents

Publication Publication Date Title
JP2024105479A5 (cg-RX-API-DMAC7.html)
Haubner et al. Honing CAR T cells to tackle acute myeloid leukemia
AU2025205147B2 (en) Blockade of CD7 expression and chimeric antigen receptors for immunotherapy of T-cell malignancies
Fidelle et al. A microbiota-modulated checkpoint directs immunosuppressive intestinal T cells into cancers
Zhao et al. Switch receptor T3/28 improves long-term persistence and antitumor efficacy of CAR-T cells
Hu et al. The transcription factor c-Myb primes CD4+ CD8+ immature thymocytes for selection into the i NKT lineage
JP2020509050A5 (cg-RX-API-DMAC7.html)
Wang et al. Innate immune cells: A potential and promising cell population for treating osteosarcoma
Zhu et al. An IL-27/NFIL3 signalling axis drives Tim-3 and IL-10 expression and T-cell dysfunction
Reinisch et al. A humanized bone marrow ossicle xenotransplantation model enables improved engraftment of healthy and leukemic human hematopoietic cells
Alfarra et al. Targeting NK cell inhibitory receptors for precision multiple myeloma immunotherapy
Leung Infusions of allogeneic natural killer cells as cancer therapy
JP2022066304A (ja) Carの抗腫瘍活性のための毒性管理
Elmas et al. CRISPR gene editing of human primary NK and T cells for cancer immunotherapy
BR112021007626A2 (pt) Receptores antigênicos quiméricos específicos pa-ra receptor acoplado à proteína g receptor de classe c, grupo 5, membro d (gprc5d)
JP2018029594A5 (cg-RX-API-DMAC7.html)
JP2017532018A (ja) MyD88およびCD40ポリペプチドによるキメラ抗原受容体の共刺激
Shin et al. Transient expression of ZBTB32 in anti-viral CD8+ T cells limits the magnitude of the effector response and the generation of memory
Polgárová et al. Chimeric antigen receptor based cellular therapy for treatment of T-cell malignancies
Kondo Autologous hematopoietic stem cell transplantation for diffuse large B-cell lymphoma
Cai et al. Microtransplantation: clinical applications and mechanisms
PE20081841A1 (es) Composiciones farmaceuticas con capacidad de induccion de apotosis en celulas tumorales, utiles para el diagnostico y tratamiento de la leucemia linfocitica cronica b
Meazza et al. XLP 1 inhibitory effect by 2 B 4 does not affect DNAM‐1 and NKG 2 D activating pathways in NK cells
Chen et al. Immunotherapy for acute myeloid leukemia: current trends, challenges, and strategies
Glez-Vaz et al. CD137 (4-1BB) requires physically associated cIAPs for signal transduction and antitumor effects